In vivo and ex vivo biodistribution data of [18F]CHDI-650 in mice

This expansion leads to an elongation of the polyglutamine tract encoding the mutant huntingtin (mHTT) protein. Based on the toxic gain-of-function hypothesis, mHTT-lowering interventions are currently among the most promising therapeutic approaches.

As part of the effort to identify a 2nd generation mHTT PET ligand, a novel fluorinated radioligand, namely [18F]CHDI-650, was recently developed. [18F]CHDI-650 displayed suitable reversible kinetics in wild-type (WT) mice and non-human primates as well as specific binding to mHTT aggregates in post-mortem human HD brain. In order to ensure the suitability of [18F]CHDI-650 in humans, a dosimetry study is generally recommended in a preclinical species to estimate the radiation exposure due to the radioligand.